Endocare Rejects Unsolicited Proposal From HealthTronics

IRVINE, Calif., Aug. 13  /PRNewswire-FirstCall/ -- Endocare, Inc. (NASDAQ:ENDO) announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. (NASDAQ:HTRN) to purchase all of the outstanding shares of Endocare for $2.28 per share.  After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.

About Endocare

Endocare, Inc. -- http://www.endocare.com/ -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation.  Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

   Investor Contact:     Media Contact:         For Additional
   Matt Clawson          Len Hall                Information:
   Allen & Caron, Inc.   Allen & Caron, Inc.    Craig T. Davenport, CEO
   [phone]        [phone]         Michael R. Rodriguez, CFO
           Endocare, Inc.
   http://www.allencaron.com/    http://www.allencaron.com/     [phone]
                                                http://www.endocare.com/

DATASOURCE: Endocare, Inc.



CONTACT:  Investor Contact, Matt Clawson, , or Len

Hall, , both of Allen & Caron, Inc., [phone], both

for Endocare, Inc.; or For Additional Information, Craig T. Davenport, CEO, or

Michael R. Rodriguez, CFO, both of Endocare, Inc., [phone]



Web site:  http://www.endocare.com/ 

Copyright